{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T19:57:46Z","timestamp":1785441466379,"version":"3.56.0"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>Cognitive impairment is increasingly recognized as having a significant influence on cancer prognosis; however, its relevance in pancreatic cancer remains underexplored. This study aims to evaluate the prevalence of cognitive impairment in patients with pancreatic cancer and examine its association with overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In this prospective study, 516 patients with newly diagnosed pancreatic cancer were enrolled. Baseline cognitive function was assessed using the Montreal Cognitive Assessment, with cognitive impairment defined as a Montreal Cognitive Assessment score &lt;24. Kaplan-Meier survival analysis and Cox proportional hazards models were used to examine the prognostic significance of cognitive impairment, adjusting for demographic and clinical covariates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The study cohort had a mean age of 64.30 years (SD=10.85), and 54.0% of the patients were diagnosed with stage IV pancreatic cancer. The median OS for the entire cohort was 17.18 months (95% CI=14.48-19.88). Cognitive impairment was observed in 53.5% of patients. Median OS was significantly shorter in patients with cognitive impairment than in those without (14.71 vs. 26.80\u00a0mo, log-rank\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt;.001). Cognitive impairment (hazard ratio=1.765, 95% CI=1.206-2.583,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      =.003) and tumor stage (hazard ratio=2.582, 95% CI=1.853-3.598,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt;.001) were independent prognostic factors for OS.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Cognitive impairment is highly prevalent and independently associated with poorer OS in pancreatic cancer. These findings support routine cognitive assessments in pancreatic cancer management and highlight the need for further investigation into underlying mechanisms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/psy.0000000000001465","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T14:00:12Z","timestamp":1766066412000},"page":"379-385","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic Value of Cognitive Impairment in Patients With Pancreatic Cancer"],"prefix":"10.1097","volume":"88","author":[{"given":"Yang-Chen","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amornthep","family":"Jankaew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Feng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Jui","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Shen","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po See","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"R1-20260730","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/ueg2.12123","article-title":"UEG position paper on pancreatic cancer. Bringing pancreatic cancer to the 21st century: prevent, detect, and treat the disease earlier and better","volume":"9","author":"Michl","year":"2021","journal-title":"United European Gastroenterol J"},{"key":"R2-20260730","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.hpb.2022.01.011","article-title":"Prognostic models to predict survival in patients with pancreatic cancer: a systematic review","volume":"24","author":"Ioannou","year":"2022","journal-title":"HPB (Oxford)"},{"key":"R3-20260730","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1093\/jnci\/djae209","article-title":"The National Cancer Institute clinical trials planning meeting to address gaps in observational and intervention trials for cancer-related cognitive impairment","volume":"117","author":"Janelsins","year":"2025","journal-title":"J Natl Cancer Inst"},{"key":"R4-20260730","doi-asserted-by":"crossref","first-page":"e2430833","DOI":"10.1001\/jamanetworkopen.2024.30833","article-title":"Cognitive symptoms across diverse cancers","volume":"7","author":"Mayo","year":"2024","journal-title":"JAMA Netw Open"},{"key":"R5-20260730","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1093\/annonc\/mdz410","article-title":"Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors","volume":"30","author":"Lange","year":"2019","journal-title":"Ann Oncol"},{"key":"R6-20260730","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1200\/JCO.2012.43.0116","article-title":"Cancer- and cancer treatment-associated cognitive change: an update on the state of the science","volume":"30","author":"Ahles","year":"2012","journal-title":"J Clin Oncol"},{"key":"R7-20260730","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3390\/cancers11050687","article-title":"Pretreatment cancer-related cognitive impairment\u2014mechanisms and outlook","volume":"11","author":"Olson","year":"2019","journal-title":"Cancers (Basel)"},{"key":"R8-20260730","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1111\/bph.15571","article-title":"Tumour brain: pretreatment cognitive and affective disorders caused by peripheral cancers","volume":"178","author":"Mampay","year":"2021","journal-title":"Br J Pharmacol"},{"key":"R9-20260730","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/jamaoncol.2017.5674","article-title":"Prevalence of cognitive impairment and association with survival among older patients with hematologic cancers","volume":"4","author":"Hshieh","year":"2018","journal-title":"JAMA Oncol"},{"key":"R10-20260730","doi-asserted-by":"crossref","first-page":"e0159734","DOI":"10.1371\/journal.pone.0159734","article-title":"Vulnerabilities in older patients when cancer treatment is initiated: does a cognitive impairment impact the two-year survival?","volume":"11","author":"Libert","year":"2016","journal-title":"PLoS One"},{"key":"R11-20260730","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.hpb.2015.09.004","article-title":"Preoperative cognitive function predicts survival in patients with resectable pancreatic ductal adenocarcinoma","volume":"18","author":"Baekelandt","year":"2016","journal-title":"HPB (Oxford)"},{"key":"R12-20260730","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/j.1532-5415.2004.52301.x","article-title":"Physician recognition of cognitive impairment: evaluating the need for improvement","volume":"52","author":"Chodosh","year":"2004","journal-title":"J Am Geriatr Soc"},{"key":"R13-20260730","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","article-title":"Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology","volume":"36","author":"Mohile","year":"2018","journal-title":"J Clin Oncol"},{"key":"R14-20260730","doi-asserted-by":"crossref","first-page":"e071726","DOI":"10.1136\/bmj-2022-071726","article-title":"Cognitive impairment after cancer treatment: mechanisms, clinical characterization, and management","volume":"380","author":"Fleming","year":"2023","journal-title":"BMJ"},{"key":"R15-20260730","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","article-title":"The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment","volume":"53","author":"Nasreddine","year":"2005","journal-title":"J Am Geriatr Soc"},{"key":"R16-20260730","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jgo.2018.08.003","article-title":"Prospective comparison of the Montreal Cognitive Assessment (MoCA) and the Mini Mental State Examination (MMSE) in geriatric oncology","volume":"10","author":"Rambeau","year":"2019","journal-title":"J Geriatr Oncol"},{"key":"R17-20260730","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.3390\/curroncol28050339","article-title":"Cognitive assessment tools recommended in geriatric oncology guidelines: a rapid review","volume":"28","author":"Tuch","year":"2021","journal-title":"Curr Oncol"},{"key":"R18-20260730","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1017\/S1041610211002298","article-title":"Psychometrics of the Montreal Cognitive Assessment (MoCA) and its subscales: validation of the Taiwanese version of the MoCA and an item response theory analysis","volume":"24","author":"Tsai","year":"2012","journal-title":"Int Psychogeriatr"},{"key":"R19-20260730","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/cncr.25514","article-title":"Screening for major depression in cancer outpatients: the diagnostic accuracy of the 9-item patient health questionnaire","volume":"117","author":"Thekkumpurath","year":"2011","journal-title":"Cancer"},{"key":"R20-20260730","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc: Ser B (Methodol)"},{"key":"R21-20260730","doi-asserted-by":"crossref","first-page":"195","DOI":"10.18203\/2349-3259.ijct20232191","article-title":"How big is a big hazard ratio in clinical trials","volume":"10","author":"Lu","year":"2023","journal-title":"Int J Clin Trials"},{"key":"R22-20260730","first-page":"88","article-title":"Lies, damned lies and statistics: clinical importance versus statistical significance in research","volume":"25","author":"Mellis","year":"2018","journal-title":"Paediatr Respir Rev"},{"key":"R23-20260730","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jgo.2020.08.001","article-title":"Shared decision-making in older patients with cancer\u2014what does the patient want?","volume":"12","author":"Rostoft","year":"2021","journal-title":"J Geriatr Oncol"},{"key":"R24-20260730","doi-asserted-by":"crossref","first-page":"676","DOI":"10.3390\/ijms20030676","article-title":"Inflammation and pancreatic cancer: focus on metabolism, cytokines, and immunity","volume":"20","author":"Padoan","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R25-20260730","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.neurobiolaging.2023.11.008","article-title":"Low-grade systemic inflammation is associated with domain-specific cognitive performance and cognitive decline in older adults: data from the TUDA study","volume":"134","author":"Dyer","year":"2024","journal-title":"Neurobiol Aging"},{"key":"R26-20260730","doi-asserted-by":"crossref","first-page":"105359","DOI":"10.1016\/j.archger.2024.105359","article-title":"C-reactive protein and cognitive impairment: a bidirectional Mendelian randomization study","volume":"121","author":"Xie","year":"2024","journal-title":"Arch Gerontol Geriatr"},{"key":"R27-20260730","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/ajco.13993","article-title":"C-reactive protein is a prognostic biomarker in pancreatic ductal adenocarcinoma patients","volume":"21","author":"Bonazzi","year":"2025","journal-title":"Asia Pac J Clin Oncol"},{"key":"R28-20260730","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4103\/sjg.SJG_390_18","article-title":"Inflammation and pancreatic cancer: an updated review","volume":"25","author":"Shadhu","year":"2019","journal-title":"Saudi J Gastroenterol"},{"key":"R29-20260730","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1002\/ijc.30252","article-title":"Cytokine-mediated blood brain barrier disruption as a conduit for cancer\/chemotherapy-associated neurotoxicity and cognitive dysfunction","volume":"139","author":"Wardill","year":"2016","journal-title":"Int J Cancer"},{"key":"R30-20260730","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.neubiorev.2020.07.002","article-title":"The microbiota-gut-brain axis: an emerging therapeutic target in chemotherapy-induced cognitive impairment","volume":"116","author":"Subramaniam","year":"2020","journal-title":"Neurosci Biobehav Rev"},{"key":"R31-20260730","doi-asserted-by":"crossref","first-page":"S301","DOI":"10.21037\/jgo-2019-gi-04","article-title":"The brain-gut axis in gastrointestinal cancers","volume":"12","author":"Alpert","year":"2021","journal-title":"J Gastrointest Oncol"},{"key":"R32-20260730","first-page":"00390","article-title":"The intestinal barrier: a pivotal role in health, inflammation, and cancer","volume":"S2468-1253","author":"Neurath","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R33-20260730","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41388-023-02909-x","article-title":"The nerve cells in gastrointestinal cancers: from molecular mechanisms to clinical intervention","volume":"43","author":"Lyu","year":"2024","journal-title":"Oncogene"},{"key":"R34-20260730","doi-asserted-by":"crossref","first-page":"111013","DOI":"10.1016\/j.cellsig.2023.111013","article-title":"The role of the gut microbiome in gastrointestinal cancers","volume":"115","author":"Mishra","year":"2024","journal-title":"Cell Signal"},{"key":"R35-20260730","doi-asserted-by":"crossref","first-page":"e143776","DOI":"10.1172\/JCI143776","article-title":"Exploiting unique features of the gut-brain interface to combat gastrointestinal cancer","volume":"131","author":"Schledwitz","year":"2021","journal-title":"J Clin Invest"},{"key":"R36-20260730","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s11739-023-03374-w","article-title":"Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review","volume":"19","author":"Di Vincenzo","year":"2024","journal-title":"Intern Emerg Med"},{"key":"R37-20260730","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12935-025-03673-6","article-title":"Inflammation, microbiota, and pancreatic cancer","volume":"25","author":"Chen","year":"2025","journal-title":"Cancer Cell Int"},{"key":"R38-20260730","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s10571-024-01496-z","article-title":"Gut-brain axis and neuroinflammation: the role of gut permeability and the kynurenine pathway in neurological disorders","volume":"44","author":"Kearns","year":"2024","journal-title":"Cell Mol Neurobiol"},{"key":"R39-20260730","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41392-024-01743-1","article-title":"Microbiota-gut-brain axis and its therapeutic applications in neurodegenerative diseases","volume":"9","author":"Loh","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"R40-20260730","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.12998\/wjcc.v11.i12.2631","article-title":"Pancreatic cancer and depression","volume":"11","author":"Michoglou","year":"2023","journal-title":"World J Clin Cases"},{"key":"R41-20260730","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1097\/MPA.0000000000001635","article-title":"Depression before and after a diagnosis of pancreatic cancer: results from a national, population-based study","volume":"49","author":"Seoud","year":"2020","journal-title":"Pancreas"},{"key":"R42-20260730","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/MPA.0000000000001024","article-title":"Early detection of pancreatic cancer: the role of depression and anxiety as a precursor for disease","volume":"47","author":"Kenner","year":"2018","journal-title":"Pancreas"},{"key":"R43-20260730","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3389\/fpsyt.2018.00299","article-title":"Biological mechanisms of cancer-induced depression","volume":"9","author":"Young","year":"2018","journal-title":"Front Psychiatry"},{"key":"R44-20260730","doi-asserted-by":"crossref","first-page":"575","DOI":"10.30773\/pi.2019.06.07","article-title":"Anhedonia and dysphoria are differentially associated with the risk of dementia in the cognitively normal elderly individuals: a prospective cohort study","volume":"16","author":"Lee","year":"2019","journal-title":"Psychiatry Investig"},{"key":"R45-20260730","doi-asserted-by":"crossref","first-page":"e2416305","DOI":"10.1001\/jamanetworkopen.2024.16305","article-title":"Bidirectional associations of depressive symptoms and cognitive function over time","volume":"7","author":"Yin","year":"2024","journal-title":"JAMA Netw Open"},{"key":"R46-20260730","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3389\/fphar.2020.00279","article-title":"Pathways connecting late-life depression and dementia","volume":"11","author":"Linnemann","year":"2020","journal-title":"Front Pharmacol"},{"key":"R47-20260730","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s13670-016-0182-9","article-title":"Cognition and cognitive impairment in older adults with cancer","volume":"5","author":"Magnuson","year":"2016","journal-title":"Curr Geriatr Rep"},{"key":"R48-20260730","doi-asserted-by":"crossref","first-page":"e0193356","DOI":"10.1371\/journal.pone.0193356","article-title":"Factor structure and measurement invariance across various demographic groups and over time for the PHQ-9 in primary care patients in Spain","volume":"13","author":"Gonz\u00e1lez-Blanch","year":"2018","journal-title":"PLoS One"},{"key":"R49-20260730","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.psychres.2018.12.048","article-title":"PHQ-9: one factor or two?","volume":"271","author":"Boothroyd","year":"2019","journal-title":"Psychiatry Res"}],"container-title":["Biopsychosocial Science and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/PSY.0000000000001465","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T19:00:25Z","timestamp":1785438025000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/PSY.0000000000001465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/psy.0000000000001465","relation":{},"ISSN":["2998-8748","2998-8756"],"issn-type":[{"value":"2998-8748","type":"print"},{"value":"2998-8756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]},"assertion":[{"value":"2025-09-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-05","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}